Hepatitis C inhibitor tri-peptides

Abstract

Racemates, diastereoisomers and optical isomers of a compound of formula (I): wherein B is H, a C 6 or C 10 aryl, C 7-16 aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C 1-6 alkyl; C 1-6 alkoxy; C 1-6 alkanoyl; hydroxy; hydroxy-alkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C 1-6 alkyl; amido; or (lower alkyl)amide; or B is an acyl derivative of formula R 4 —C(O)—; a carboxyl of formula R 4 —O—C(O)—; an amide of formula R 4 —N(R 5 )—C(O)—; a thioamide of formula R 4 —N(R 5 )—C(S)—; or a sulfonyl of formula R 4 —SO 2 ; R 5 is H or C 1-6 alkyl; and Y is H or C 1-6 alkyl; R 3 is C 3-7 cycloalkyl, or C 4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C 1-6 alkoxy, C 1-6 thioalkyl, amido, (lower alkyl)amido, C 6 or C 10 aryl, or C 7-16 aralkyl; R 2 is CH 2 —R 20 , NH—R 20 , O—R 20 or S—R 20 , wherein R 20 is a saturated or unsaturated C 3-7 cycloalkyl or C 4-10 (alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with R 21 , or R 20 is a C 6 or C 10 aryl or C 7-14 aralkyl optionally substituted, or R 20 is Het or (lower alkyl)-Het, both optionally substituted, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C 6 or C 10 aryl, C 7-14 aralkyl or Het, said aryl, aralkyl or Het being optionally substituted; and R 1 is H; C 1-6 alkyl, C 3-7 cycloalkyl, C 2-6 alkenyl, or C 2-6 alkynyl, all optionally substituted with halogen; or a pharmaceutically acceptable salt or ester thereof.

1. A racemate, diastereoisomer or optical isomer of a compound of formula (I): 
                 
 wherein  
 B is H, a C 6  or C 10  aryl, C 7-16  aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C 1-6  alkyl; C 1-6  alkoxy; C 1-6  alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C 1-6  alkyl; amido; or (lower alkyl)amide;  
 or B is an acyl derivative of formula R 4 —C(O)—; a carboxyl derivative of formula R 4 —O—C(O)—; an amide derivative of formula R 4 —N(R 5 )—C(O)—; a thioamide derivative of formula R 4 —N(R 5 )—C(S)—; or a sulfonyl derivative of formula R 4 —SO 2  wherein 
 R 4  is 
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl, hydroxy, C 1-6  alkoxy, amino optionally mono- or di-substituted with C 1-6  alkyl, or amido, or (lower alkyl) amide ; and when B is R 4   —O—C ( O ) —; R   4   —N ( R   5 ) —C ( O ) —; R   4   —N ( R   5 ) —C ( S ) —; or R   4   —SO   2   , then R   4    may additionally be selected from C   1-10    alkyl substituted with  ( lower alkyl )  amide;   
 (ii) C 3-7  cycloalkyl, or C 3-7  cycloalkoxy, or C 4-10  alkylcycloalkyl,  all optionally substituted with hydroxy, carboxyl, (C 1-6  alkoxy)carbonyl, amino optionally mono- or di-substituted with C 1-6  alkyl, amido, or (lower alkyl) amide; or R 4    is C   4-10    alkylcycloalkyl, optionally substituted with hydroxy, carboxyl,  ( C   1-6    alkoxy ) carbonyl, amino optionally mono -  or di - substituted with C   1-6    alkyl, or amido; and when B is R   4   —O—C ( O ) —; R   4   —N ( R   5 ) —C ( O )—;  R   4   —N ( R   5 )— C ( S )— ; or R   4   —SO   2   , then R   4    may additionally be C   4-10    alkylcycloalkyl substituted with  ( lower alkyl )  amide;    
 (iii) amino optionally mono- or di-substituted with C 1-6  alkyl; amido; or (lower alkyl)amide;  
 (iv) C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C 1-6  alkyl; or  
 (v) Het or (lower alkyl)-Het, both optionally substituted with C 1-6  alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 
 R 5  is H or C 1-6  alkyl; with the proviso that when B is a carboxyl derivative, an amide derivative or a thioamide derivative, R 4  is not a cycloalkoxy;  
 
 Y is H or C 1-6  alkyl;  
 R 3  is C 1-8  alkyl, C 3-7  cycloalkyl, or C 4-10  alkylcycloalkyl, all optionally substituted with hydroxy, C 1-6  alkoxy, C 1-6  thioalkyl, amido, (lower alkyl)amido, C 6  or C 10  aryl, or C 7-16  aralkyl;  
 R 2  is CH 2 —R 20 , NH—R 20 , O—R 20  or S—R 20 , wherein R 20  is pyrimidinyl, quinazolinyl, (lower alkyl)-pyrimidinyl or (lower alkyl)-quinazolinyl, each optionally mono-, di- or tri-substituted with R 21 , 
 wherein each R 21  is independently C 1-6  alkyl; C 1-6  alkoxy; lower thioalkyl; sulfonyl;  NO 2 ; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C 1-6  alkyl, C 6  or C 10  aryl, C 7-14  aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with C 1-6  alkyl, C 6  or C 10  aryl, C 7-14  aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C 6  or C 10  aryl, C 7-14  aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R 22 ; 
 wherein R 22  is C 1-6  alkyl; C 3-7  cycloalkyl; C 1-6  alkoxy; amino optionally mono- or di-substituted with C 1-6  alkyl; sulfonyl;  (lower alkyl)sulfonyl; NO 2 ; OH; SH; halo; haloalky; carboxyl; amide;  amido; (lower alkyl)amide; or Het optionally substituted with C 1-6  alkyl;  
 
 
 R 1  is H; C 1-6  alkyl, C 3-7  cycloalkly  C 3-7    cycloalkyl, C   2-6    alkenyl , or C 2-6  alkynyl, all optionally substituted with halogen;  
 
       or a pharmaceutical acceptable salt or ester thereof; 
       wherein “Het” is defined as a five-membered saturatd  saturated or unsaturated, aromatic or non-aromatic, heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur, wherein said heterocycle is optionally fused to a benzene ring. 
     
     
       2. A compound of formula  1  according to  claim 1 , wherein
 B is a C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, C 1-6  alkoxy, C 1-6  alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with alkyl; or  
 B is Het or (lower alkyl)-Het, all optionally substituted with C 1-6  alkyl, C 1-6  alkoxy, alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C 3-6  alkyl.  
 
     
     
       3. A compound of formula I according to  claim 1 , wherein B is R 4 —SO 2  wherein R 4  is C 1-6  alkyl; amido; (lower alkyl)amide; C 6  or C 10  aryl, C 7-14  aralkyl or Het, all optionally substituted with C 1-6  alkyl. 
     
     
       4. A compound of formula I according to  claim 1 , wherein B is an acyl derivative of formula R 4 —C(O)— wherein R 4  is
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6    alkanoyl,  hydroxyor , C 1-6  alkoxy, amido, (lower alkyl)amide,  or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, both  optionally substituted with hydroxy, carboxyl, (C 1-6  alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C 1-6  alkyl; or C 4-10    alkylcycloalkyl, optionally substituted with hydroxy, carboxyl,  ( C   1-6    alkoxy ) carbonyl, amino optionally mono -  or di - substituted with C   1-6    alkyl, or amido;    
 (iv)  (iii) C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substitutedmono-  or di - substituted  with C 1-6  alkyl; or  
 (v)  (iv) Het or (lower alkyl)-Het, both optionally substituted with C 1-6  alkyl, hydroxy, amino optionally substitutedmono-  or di - substituted  with C 1-6  alkyl, amido, or (lower alkyl)amide, or amino optionally substituted with C 1-6  alkyl .  
 
     
     
       5. A compound of formula I according to  claim 1 , wherein B is a carboxyl derivative of formula R 4 —O—C(O)—, wherein R 4  is
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl, hydroxy, C 1-6  alkoxy, amino optionally mono- or di-substituted with C 1-6  alkyl, amido or (lower alkyl)amide;  
 (ii) C 3-7  cycloalkyl, C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy)carbonyl, amino optionally mono- or di-substituted with C 1-6  alkyl, amido or (lower alkyl)amide;  
 (iv)  (iii) C 6  or C 10  aryl or C 7-16  aralkyl optionally substituted with C 1-6  alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C 1-6  alkyl; or  
 (v)  (iv) Het or (lower alkyl)-Het, both optionally substituted with C 1-6  alkyl, hydroxy, amino optionally mono- or di-substituted with C 1-6  alkyl, amido or (lower alkyl) amido.  
 
     
     
       6. A compound of formula I according to  claim 1 , wherein B is an amide derivative of formula R 4 —N(R 5 )—C(O)— wherein R 4  is
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl, hydroxy, C 1-6  alkoxy, amido, (lower alkyl) amido, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy)carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (iii) amino optionally mono- or di-substituted with C 1-3  alkyl;  
 (iv) C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally substituted with C 1-6  alkyl; or  
 (v) Het or (lower alkyl)-Het, both optionally substituted with C 1-6  alkyl, hydroxy, amino optionally substituted with C 1-6  alkyl, amido or (lower alkyl)amide; and  
 R 5  is H or methyl.  
 
     
     
       7. A compound of formula I according to  claim 1 , wherein B is a thioamide derivative of formula R 4 —NH—C(S)—; wherein R 4  is
 (i) CC 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl or C 1-6  alkoxy;  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy)carbonyl, amino or amido.  
 
     
     
       8. A compound of formula I according to  claim 2 , wherein B is a C 6  or C 10  aryl optionally substituted with C 1-6  alkyl, C 1-6  alkoxy, C 1-6  alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C 1-6  alkyl. 
     
     
       9. A compound of formula I according to  claim 2 , wherein r  B is Het optionally substituted with C 1-6  alkyl, C 1-6  alkoxy, C 1-6  alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C 1-6  alkyl. 
     
     
       10. A compound of formula I according to  claim 4 , wherein B is an acyl derivative of formula R 4 —C(O)— wherein R 4  is
 (i) C 1-10  alkyl optionally substituted with carboxyl, hydroxy or C 1-6  alkoxy, or  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, or (C 1-6  alkoxy) carbonyl, or  
 (iv)  (iii) C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, or hydroxy, or  
 (v)  (iv) Het optionally substituted with C 1-6  alkyl, hydroxy, amido or amino.  
 
     
     
       11. A compound of formula I according to  claim 5 , wherein B is a carboxyl derivative of formula R 4 —O—C (O)—, wherein R 4  is
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl, hydroxy, C 1-6  alkoxyor , amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (ii) C 3-7  cycloalkyl, C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C 1-6  alkyl, or  
 (iv)  (iii) C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, hydroxy, or amino optionally substituted with C 1-6  alkyl; or  
 (v)  (iv) Het or (lower alkyl)-Het, both optionally substituted with C 1-6  alkyl, hydroxy, amido, or amino optionally mono-substituted with C 1-6  alkyl.  
 
     
     
       12. A compound of formula I according to  claim 6 , wherein B is an amide derivative of formula R 4 —N(R 5 )—C(O)— wherein R 4  is
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl, hydroxy, C 1-6  alkoxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (iii) amino optionally mono- or di-substituted with C 1-3  alkyl, or  
 (iv) C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, hydroxy, amino or amido optionally substituted with C 1-6  alkyl; or  
 (v) Het optionally substituted with C 1-6  alkyl, hydroxy, amino or amido,  
 and R 5  is H.  
 
     
     
       13. A compound of formula I according to  claim 7 , wherein B is a thioamide derivative of formula R 4 —NH—C(S)—; wherein R 4  is (i) C 1-10  alkyl; or (ii) C 3-7  cycloalkyl. 
     
     
       14. A compound of formula I according to  claim 12 , wherein B is an amide derivative of formula R 4 —NH—C (O)— wherein R 4  is
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl, hydroxy, C 1-6  alkoxy amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C 1-6  alkyl; or  
 (iv)  (iii) C 6  or C 10  aryl or C 7-16  aralkyl optionally substituted with C 1-6  alkyl, hydroxy, amino or amido.  
 
     
     
       15. A compound of formula I according to  claim 1 , wherein B is 
                 
 
     
     
       16. A compound of formula I according to  claim 1 , wherein Y is H or methyl. 
     
     
       17. A compound of formula I according to  claim 16 , wherein Y is H. 
     
     
       18. A compound of formula I according to  claim 1 , wherein R 3  is C 1-8  alkyl, C 3-7  cycloalkyl, or C 4-10  alkylcycloalkyl, all optionally substituted with hydroxy, C 1-6  alkoxy, C 1-6  thioalkyl, acetamido, C 6  or C 10  aryl, or C 7-16  aralkyl. 
     
     
       19. A compound of formula I according to  claim 18 , wherein R 3  is the side chain of Tbg, Ile, Val, Chg or: 
                 
 
     
     
       20. A compound of formula I according to  claim 19 , wherein R 3  is the side chain of Tbg, Chg or Val. 
     
     
       21. A compound of formula I according to  claim 1 , wherein R 2  is S—R 20  or O—R 20  wherein R 20  is a pyrimidinyl, quinazolinyl, —CH 2 -pyrimidinyl or —CH 2 -quinazolinyl, all optionally mono, di- or tri-substituted with R 21 , wherein
 R 21  is C 1-6  alkyl; C 1-6  alkoxy; lower thioalkyl; amino or  optionally mono-  or di - substituted with C   1-6    alkyl, C   6    or C   10    aryl, C   7-16    aralkyl, Het or  ( lower alkyl )- Het;  amido optionally mono-or di-substituted  mono- substituted  with C 1-6  alkyl, C 6  or C 10  aryl, C 7-16  aralkyl, Het or (lower alkyl)-Het; NO 2 ; OH; halo; trifluoromethyl; carboxyl; C 6  or C 10  aryl, C 7-16  aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R 22 , wherein 
 R 22  is C 1-6  alkyl; C 3-7  cycloalkyl; C 1-6  alkoxy; amino; mono- or di-(lower alkyl)amino; amido; (lower alkyl)amide; sulfonylalkyl;  (lower alkyl) sulfonyl;  NO 2 ; OH; halo; trifluoromethyl; carboxyl or Het.  
 
 
     
     
       22. A compound of formula I according to  claim 21 , wherein R 21  is alkyl; C 1-6  alkoxy; amino; di(lower alkyl)amino; (lower alkyl)amide; C 6  or C 10  aryl, or Het, said aryl or Het being optionally substituted with R 22 , wherein R 22  is C 1-6  alkyl; C 3-7  cycloalkyl; alkoxy, amino; mono- or di (lower alkyl)amino; amido; (lower alkyl)amide; halo; trifluoromethyl or Het. 
     
     
       23. A compound of formula I according to  claim 22 , wherein R 22  is C 1-6  alkyl; C 1-6  alkoxy; halo; amino optionally mono- or di-substituted with lower alkyl; amido; (lower alkyl)amide; or Het. 
     
     
       24. A compound of formula I according to  claim 23 , wherein R 22  is methyl; ethyl; isopropyl; tert-butyl; methoxy; chloro; amino optionally mono- or di-substituted with lower alkyl; amido, or (lower alkyl)amide; or (lower alkyl) 2-thiazole . 
     
     
       25. A compound of formula I according to  claim 21 , wherein R 2  selected from the group consisting of: 
                 
 
     
     
       26. A compound of formula I according to  claim 1 , wherein R 1  is H, C 1-3  alkyl, C 3-5  cycloalkyl, or C 2-4  alkenyl, all optionally substituted with halo. 
     
     
       27. A compound of formula I according to  claim 26 , wherein P1 is: 
                 
 and R 1  is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl.  
 
     
     
       28. A compound of formula I according to  claim 27 , wherein R 1  is vinyl. 
     
     
       29. A compound of formula I according to  claim 27 , wherein R 1  at carbon 2 is orientated syn to the carbonyl at position 1, represented by the radical: 
                 
 
     
     
       30. A compound of formula I according to  claim 27 , wherein R 1  at position 2 is orientated anti to the carbonyl at position 1, represented by the radical: 
                 
 
     
     
       31. A compound of formula I according to  claim 27 , wherein carbon 1 has the R configuration: 
                 
 
     
     
       32. An optical isomer of a compound of formula I according to  claim 31 , wherein said R 1  substituent and the carbonyl are in a syn orientation in the following absolute configuration: 
                 
 
     
     
       33. A compound of formula I according to  claim 32 , wherein R 1  is ethyl, hence the asymmetric carbon atoms at positions 1 and 2 have the R,R configuration. 
     
     
       34. A compound of formula I according to  claim 32 , wherein R 1  is vinyl, hence the asymmetric carbon atoms at positions 1 and 2 have the R,S configuration. 
     
     
       35. A compound of formula I according to  claim 1 , wherein
 B is a C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, C 1-6  alkoxy, C 1-6  alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C 1-6  alkyl; or  
 B is Het or (lower alkyl)-Het, all optionally substituted with C 1-6  alkyl, C 1-6  alkoxy, C 1-6  alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C 1-6  alkyl, or  
 B is R 4 —SO 2  wherein R 4  is amido; (lower alkyl)amide; C 6  or C 10  aryl, C 7-14  aralkyl or Het, all optionally substituted with C 1-6  alkyl, or  
 B is an acyl derivative of formula R 4 —C(O)— wherein R 4  is 
 (i) C 1-10  alkyl optionally substituted with carboxyl, hydroxyor , C 1-6  alkoxy, amido, (lower alkyl)amide,  or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, both  optionally substituted with hydroxy, carboxyl, (C 1-6  alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C 1-6  alkyl; or C 4-10    alkylcycloalkyl, optionally substituted with hydroxy, carboxyl,  ( C   1-6    alkoxy ) carbonyl, amido or amino optionally mono -  or di - substituted with C   1-6    alkyl,   
 (iv)  (iii) C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substitutedmono-  or di - substituted  with C 1-6  alkyl;  
 (v)  (iv) Het or (lower alkyl)-Het, both optionally substituted with C 1-6  alkyl, hydroxy, amino optionally substituted with C 1-6  alkyl,  amido, (lower alkyl)amide, or amino optionally substitutedmono-  or di - substituted  with C 1-6  alkyl, or  
 
 B is a carboxyl derivative of formula R 4 —O—C(O)—, wherein R 4  is 
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl, hydroxy, C 1-6  alkoxy, amino optionally mono- or di-substituted with C 1-6  alkyl, amido or (lower alkyl)amide;  
 (ii) C 3-7  cycloalkyl, C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy) carbonyl, amino optionally mono- or di-substituted with C 1-6  alkyl, amido or (lower alkyl)amide;  
 (iv)  (iii) C 6  or C 10  aryl or C 7-16  aralkyl, both optionally substituted with C 1-6  alkyl, hydroxy, amido, (lower alkyl) amido, or amino optionally mono- or di-substituted with C 1-6  alkyl; or  
 (v)  (iv) Het or (lower alkyl)-Het, both optionally substituted with C 1-6  alkyl, hydroxy, amino optionally mono- or di-substituted with C 1-6  alkyl, amido or (lower alkyl) amido, or  
 
 B is an amide derivative of formula R 4 —N(R 5 )—C(O)— wherein R 4  is 
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl, hydroxy, C 1-6  alkoxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy) carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C 1-6  alkyl;  
 (iii) amino optionally mono- or di-substituted with C 1-3  alkyl;  
 (iv) C 6  or C 10  aryl or C 7-16  aralkyl, all optionally substituted with C 1-6  alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted  mono-  or di - substituted  with C 1-6  alkyl; or  
 (v) Het or (lower alkyl)-Het, both optionally substituted with C 1-6  alkyl, hydroxy, amino optionally substituted  mono-  or di - substituted  with C 1-6  alkyl, amido or (lower alkyl)amide; and  
 
 R 5  is H or methyl, or  
 B is thioamide derivative of formula R 4 —NH—C(S)—; wherein R 4  is 
 (i) C 1-10  alkyl optionally substituted with carboxyl, C 1-6  alkanoyl or C 1-6  alkoxy;  
 (ii) C 3-7  cycloalkyl or C 4-10  alkylcycloalkyl, all optionally substituted with carboxyl, (C 1-6  alkoxy) carbonyl, amino or amido;  
 
 Y is H or methyl;  
 R 3  is C 1-8  alkyl, C 3-7  cycloalkyl, or C 4-10  alkylcycloalkyl, all optionally substituted with hydroxy, C 1-6  alkoxy, C 1-6  thioalkyl, acetamido, C 6  or C 10  aryl, or C 7-16  aralkyl;  
 R 2  is S—R 20  or O—R 20  wherein R 20  is pyrimidinyl, quinazolinyl, —CH 2 -pyrimidinyl or —CH 2 -pyrimidinyl or  —CH 2 —quinazolinyl, all optionally mono-, di- or tri-substituted with R 21 , wherein 
 R 21  is C 1-6  alkyl; C 1-6  alkoxy; lower thioalkyl; amino or amido optionally mono-or di-substituted with C 1-6  alkyl, C 6  or C 10  aryl, C 7-16   C 7-14  aralkyl, Het or (lower alkyl)-Het; NO 2 ; OH; halo; trifluoromethyl; carboxyl; C 6  or C 10  aryl, C 7-16  aralkyl, or Het,  said aryl, aralkyl or Het being optionally substituted with R 22 , wherein 
 R 22  is C 1-6  alkyl; C 3-7  cycloalkyl; C 1-6  alkoxy; amino; mono- or di-(lower alkyl)amino; (lower alkyl)amide; sulfonylalkyl  (lower alkyl) sulfonyl ; NO 2 ; OH; halo; trifluoromethyl; carboxyl or Het; or  
 
 
 R 2  is selected from the group consisting of: 
                 
 wherein R 1  is H, C 1-3  alkyl, C 3-5  cycloalkyl, or C 2-4  alkenyl optionally substituted with halo, and said R 1  at carbon 2 is orientated syn to the carbonyl  carboxy at position 1, represented by the radical: 
                 
 
 
 
       or a pharmaceutically acceptable salt or ester thereof. 
     
     
       36. A compound according to  claim 35  represented by the formula: 
                 
 
       wherein B [R 3 , R 2  and R 1 ]  R 3 , R 2  and R 1  are as defined below:
                                                   R 1 R 1       Table 3               syn to     Cpd #   B   R 3 R 3     R 2 R 2     carboxyl           301   Boc   cHex   —O—CH 2 -1-naphthyl   ethyl;     302                         iPr   —O—CH 2 -1-naphthyl   ethyl;     303                         cHex   —O—CH 2 -1-naphthyl   ethyl;     304   Boc   cHex                         ethyl;     305   Boc   cHex   —O—CH 2 -1-naphthyl   vinyl;     306   Boc   cHex                         vinyl;     307   Boc   cHex                         vinyl;     308   Boc   cHex                         vinyl;     309   Boc   cHex                         vinyl;     310   Boc   cHex                         vinyl;     311   Boc   cHex                         vinyl;     312   Boc   cHex                         vinyl;     313   Boc   cHex                         vinyl;     314   Boc   cHex                         vinyl;     315   Boc   cHex                         vinyl;     316   Acetyl   cHex                         vinyl;     317   Boc   cHex                         vinyl;     318   CF 3 —C(O)—   i-Pr                         vinyl;      319                         cHex                         vinyl;     320                         cHex                         vinyl;     321   Boc   t-Bu                         vinyl;     322   Boc   t-Bu                         vinyl;      323   Boc   t-Bu                                                 324   Boc   t-Bu                         vinyl;      325   Boc   t-Bu                                                 324     Boc       t-Bu                             vinyl;       326   Boc   t-Bu                         vinyl.     327                         t-Bu                         vinyl;     328   Boc   t-Bu                         vinyl;     329   Boc   t-Bu                         vinyl;     330   Boc   t-Bu                         vinyl;     331                         t-Bu                         vinyl;     332   Boc   t-Bu                         ethyl;     333                         t-Bu                         vinyl;     and 334                         t-Bu                         vinyl                                                                  
 
     
     
       37. A compound according to  claim 36 , selected from the group consisting of compound #: 319, 321, and 326. 
     
     
       38. A pharmaceutical composition comprising an anti-hepatitis C virally effective amount of a compound of a compound of formula I according to  claim 1 , or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxilliary agent. 
     
     
       39. A method of treating a hepatitis C viral infection in a mammal comprising administering to the mammal an anti-hepatitis C virally effective amount of the compound of formula I according to  claim 1 , or a therapeutically acceptable salt or ester thereof. 
     
     
       40. A method of treating a hepatitis C viral infection in a mammal comprising administering to the mammal an anti-hepatitis C virally effective amount of the composition according to claim  39    38 . 
     
     
       41. A method of inhibiting the replication of hepatitis C virus comprising exposing the virus to a hepatitis C viral NS3 protease inhibiting amount of the compound of formula I according to  claim 1 , or a therapeutically acceptable salt or ester thereof. 
     
     
       42. A method of treating a hepatitis C viral infection in a mammal comprising administering thereto an anti-hepatitis C virally effective amount of a combination of the compound of formula I according to  claim 1 , or a therapeutically acceptable salt or ester thereof with another anti-HCV agent. 
     
     
       43. A method according to  claim 42 , wherein said other anti-HCV agent is selected from the group consisting of: α- or β-interferon, ribavirin and amantadine. 
     
     
       44. A method according to  claim 42 , wherein said other anti-HCV agent comprises an inhibitor of other targets in the HCV life cycle, selected from: helicase, polymerase, metalloprotease or IRES. 
     
     
       45. A process for the preparation of a peptide analog  compound of formula (I) according to  claim 1  wherein P1 is a substituted aminocyclopropyl carboxylic acid residue, comprising the step of:
 coupling a peptide selected from the group consisting of: 
 APG-P3-P2; or APG-P2; with a P1 intermediate of formula: 
                 
 
 wherein R 1  is C 1-6  alkyl, cycloalkyl or C 2-6  alkenyl, all optionally substituted with halogen, CPG is a carboxyl protecting group an APG is an amino protecting group an P3 an P2 are as defined above.  
 
 
     
     
       46. A process for the preparation of: a peptide analog  compound of formula (I) according to  claim 1 , this process comprising the step of:
 coupling a suitably protected amino acid, peptide or peptide fragment with a P1 intermediate of formula: 
                 
 wherein R 1  is C 1-6  alkyl, cycloalkyl or C 2-6  alkenyl, all optionally substituted with halogen, and CPG is a carboxyl protecting group.  
 
 
     
     
       47. A process for the preparation of: a peptide analog  compound of formula (I) according to  claim 1 , this process comprising the step of:
 coupling a suitably protected amino acid, peptide or peptide fragment with a P1 intermediate of formula: 
                 
 wherein CPG is a carboxyl protecting group.  
 
 
     
     
       48. The process according to  claim 45 ,  46  or  47  wherein said carboxyl protecting group (CPG) is selected from the group consisting of:
 alkyl esters, aralkyl esters, and esters being cleavable by mild base treatment or mild reductive means.  
 
     
     
       49. Method of preparing a composition for treating a hepatitis C viral infection in a mammal comprising combining an anti-hepatitis C virally effective amount of the compound of formula I according to  claim 1 , or a therapeutically acceptable salt or ester thereof, with a pharmaceutically acceptable carrier medium or auxiliary agent. 
     
     
       50. Method of preparing a composition for inhibiting the replication of hepatitis C virus comprising combining a hepatitis C viral NS3 protease inhibiting amount of the compound of formula I according to  claim 1 , or a therapeutically acceptable salt or ester thereof, with a pharmaceutically acceptable carrier medium or auxiliary agent. 
     
     
       51. Method of preparing a composition for treating a hepatitis C viral infection in a mammal comprising combining an anti-hepatitis C virally effective amount of a combination of the compound of formula I according to  claim 1 , or a therapeutically acceptable salt or ester thereof, and an interferon with a pharmaccutically acceptable carrier medium or auxiliary agent. 
     
     
       52. A compound of formula (I) according to  claim 1 , wherein each Het group is independently selected from the group consisting of pyrrolidine, tetrahydrofuran, thiazolidine, pyrrole, 1,4-dioxane, indole, or any of the following heterocycles: